Beclometasone dipropionate is a potent glucocorticoid agonist; it is a prodrug of the free form, beclometasone.

Becampanel (AMP 397) potent, competitive antagonist of the AMPA receptor (AMPAR) with IC50 of 11 nM.

Beauvericin is a cyclic hexadepsipeptide with antibiotic and insecticidal effects, shows activity against Gram-positive bacteria and mycobacteria, and is also capable of inducing programmed cell death in mammals..

BDP-NAC is a novel persulfide donor that shows selectivity towards H2 O2 over other potential oxidative or nucleophilic triggers, resulting in the sustained release of the persulfide of N-acetyl cysteine (NAC).

BCX-1470 (BCX1470) is a serine protease inhibitor that inhibits the esterolytic activity of factor D (IC50=96 nM) and C1s (IC50=1.6 nM).

BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo..

BCL6-IN-8 (BCL6-i) is a potent, irreversible and cell-active BCL6 inhibitor with inact/KI value of 1.9 × 104 M-1 s-1, targets Cys53 located at the protein-protein interaction interface.

BCL6 PROTAC 15 is a novel B-cell lymphoma 6 (BCL6) PROTAC, significantly degrade BCL6 in a number of DLBCL cell lines, but neither BCL6 inhibition nor degradation selectively induces marked phenotypic response.

BCL6 inhibitor 14 is a potent BCL-6 inhibitor with FRET IC50 of 63 nM..

BCI-137 is a chemical compound able to compete with Argonaute 2 miRNAs binding, binds to Ago2 with Kd of 126 uM.

BC-23 (NSC 45382) is a novel inhibitor of β-catenin/Tcf4 interaction with IC50 of 1.7 uM.

BC-21 (NSC 109268) is a novel small molecule inhibitor that effectively inhibits the β-catenin/Tcf4 interaction with Ki of 6.55 uM.

BC-1485 is a first-in-class, small molecule inhibitor of FIEL1 (Fibrosis-inducing E3 ligase 1) that exhibits potent activity toward disrupting FIEL1-directed PIAS4 ubiquitination.

BB-Cl-Amidine is a peptidylarginine deminase (PAD) inhibitor.

BAY-826 (BAY826) is a novel selective, highly potent, orally available TIE-2 inhibitor (dissociation constant=1.6 nM).

BAY-7598 (BAY7598) is a potent, selective MMP12 inhibitor..

BAY-707 is a highly potent, selective and substrate-competitive inhibitor of MTH1 (NUDT1) with IC50 of 2.3 nM.

BAY-678 racemate is a chemical probe candidate for Human Neutrophil Elastase (HNE).

BAY-524 (BAY524) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 450 nM.

BAY-386 (BAY386) is a potent, specific and reversible PAR-1 antagonist with IC50 of 10 nM (HEK cell) and binding IC50 of 56 nM, without affinity for PAR-4 (IC50>10 uM).

BAY-320 (BAY320) is a potent, selective, ATP-competitive inhibitor of Bub1 kinase with IC50 of 680 nM.

BAY-293 racemate (BAY293 racemate) is a potent SOS1 inhibitor that disrupts the KRAS-SOS1 interaction with IC50 of 50 nM, the R-enantiomer (BAY-293) is the active form with IC50 of 21 nM, while the BAY-293 is less active (IC50=2,340 nM)..

BAY 60-6583 (BAY606583) is a potent, selective adenosine A2B receptor agonist with EC50 of 2.83 nM (murine A2BR).

BAY 60-2770 is an NO-independent activator of sGC (soluble guanylyl cyclase) with EC50 of 5.4 nM.

BAY 41-8543 is an NO-independent sGC (soluble guanylyl cyclase) stimulator, inhibits collagen-mediated aggregation in washed human platelets (IC50=90 nM).

Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

BAY 1238097 is a novel BET bromodomain inhibitor with IC50 of 50 nM, inhibits the interaction between BRD4, BRD3 or BRD2 and H4 with IC50 values of 63 nM, 609 nM and 2430 nM in the NanoBRET assay.

BAY 1143269 is a potent, selective, orally bioavailable inhibitor of MNK1 with enzyme IC50 of 40 nM at 2 mM ATP.

BAY 1024767 (BAY1024767) is a higly potent antagonist of androgen receptor (AR) wild-type (IC50=46 nM) and mutant forms located in the AR ligand-binding domain (LBD).

Balsalazide is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.